NCT00044538View on ClinicalTrials.gov

Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

December 31, 2001

Study Completion Date

June 30, 2004

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

BAY59-8862 (Cytotoxic Taxane)

Intravenous dose over 60 minutes every 3 weeks

Trial Locations (27)

10126

Torino

13353

Berlin

28034

Madrid

28040

Madrid

33100

Udine

37205

Nashville

40202

Louisville

41100

Modena

43100

Parma

43235

Columbus

44281

Kfar Saba

48903

Barakaldo

52621

Tel Litwinsky

56126

Pisa

64239

Tel Aviv

70006

Metairie

82131

Gauting

85712

Tucson

06708-2904

Waterbury

14263-0001

Buffalo

T6G 1Z2

Edmonton

L8V 5C2

Hamilton

P7A 7T1

Thunder Bay

H3T 1E2

Montreal

G1V 4G5

Québec

03203

Elche

08036

Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY

NCT00044538 - Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients | Biotech Hunter | Biotech Hunter